Cargando…
Preventing Left Ventricular Hypertrophy by ACE Inhibition in Hypertensive Patients With Type 2 Diabetes: A prespecified analysis of the Bergamo Nephrologic Diabetes Complications Trial (BENEDICT)
OBJECTIVE—In patients with type 2 diabetes, left ventricular hypertrophy (LVH) predicts cardiovascular events, and the prevention of LVH is cardioprotective. We sought to compare the effect of ACE versus non-ACE inhibitor therapy on incident electrocardiographic (ECG) evidence of LVH (ECG-LVH). RESE...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
American Diabetes Association
2008
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2494629/ https://www.ncbi.nlm.nih.gov/pubmed/18443191 http://dx.doi.org/10.2337/dc08-0371 |
_version_ | 1782158234790920192 |
---|---|
author | Ruggenenti, Piero Iliev, Ilian Costa, Grazia Maria Parvanova, Aneliya Perna, Annalisa Giuliano, Giovanni Antonio Motterlini, Nicola Ene-Iordache, Bogdan Remuzzi, Giuseppe |
author_facet | Ruggenenti, Piero Iliev, Ilian Costa, Grazia Maria Parvanova, Aneliya Perna, Annalisa Giuliano, Giovanni Antonio Motterlini, Nicola Ene-Iordache, Bogdan Remuzzi, Giuseppe |
author_sort | Ruggenenti, Piero |
collection | PubMed |
description | OBJECTIVE—In patients with type 2 diabetes, left ventricular hypertrophy (LVH) predicts cardiovascular events, and the prevention of LVH is cardioprotective. We sought to compare the effect of ACE versus non-ACE inhibitor therapy on incident electrocardiographic (ECG) evidence of LVH (ECG-LVH). RESEARCH DESIGN AND METHODS—This prespecified study compared the incidence of ECG-LVH by Sokolow-Lyon and Cornell voltage criteria in 816 hypertensive type 2 diabetic patients of the Bergamo Nephrologic Diabetes Complications Trial (BENEDICT), who had no ECG-LVH at baseline and were randomly assigned to at least 3 years of blinded ACE inhibition with trandolapril (2 mg/day) or to non-ACE inhibitor therapy. Treatment was titrated to systolic/diastolic blood pressure <130/80 mmHg. ECG readings were centralized and blinded to treatment. RESULTS—Baseline characteristics of the two groups were similar. Over a median (interquartile range) follow-up of 36 (24–48) months, 13 of the 423 patients (3.1%) receiving trandolapril compared with 31 of the 376 patients (8.2%) receiving non-ACE inhibitor therapy developed ECG-LVH (hazard ratio [HR] 0.34 [95% CI 0.18–0.65], P = 0.0012 unadjusted, and 0.35 [0.18–0.68], P = 0.0018 adjusted for predefined baseline covariates). The HR was significant even after adjustment for follow-up blood pressure and blood pressure reduction versus baseline. Compared with baseline, both Sokolow-Lyon and Cornell voltages significantly decreased with trandolapril but did not change with non-ACE inhibitor therapy. CONCLUSIONS—ACE inhibition has a specific protective effect against the development of ECG-LVH that is additional to its blood pressure–lowering effect. Because ECG-LVH is a strong cardiovascular risk factor in people with hypertension and diabetes, early ACE inhibition may be cardioprotective in this population. |
format | Text |
id | pubmed-2494629 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2008 |
publisher | American Diabetes Association |
record_format | MEDLINE/PubMed |
spelling | pubmed-24946292009-08-01 Preventing Left Ventricular Hypertrophy by ACE Inhibition in Hypertensive Patients With Type 2 Diabetes: A prespecified analysis of the Bergamo Nephrologic Diabetes Complications Trial (BENEDICT) Ruggenenti, Piero Iliev, Ilian Costa, Grazia Maria Parvanova, Aneliya Perna, Annalisa Giuliano, Giovanni Antonio Motterlini, Nicola Ene-Iordache, Bogdan Remuzzi, Giuseppe Diabetes Care Cardiovascular and Metabolic Risk OBJECTIVE—In patients with type 2 diabetes, left ventricular hypertrophy (LVH) predicts cardiovascular events, and the prevention of LVH is cardioprotective. We sought to compare the effect of ACE versus non-ACE inhibitor therapy on incident electrocardiographic (ECG) evidence of LVH (ECG-LVH). RESEARCH DESIGN AND METHODS—This prespecified study compared the incidence of ECG-LVH by Sokolow-Lyon and Cornell voltage criteria in 816 hypertensive type 2 diabetic patients of the Bergamo Nephrologic Diabetes Complications Trial (BENEDICT), who had no ECG-LVH at baseline and were randomly assigned to at least 3 years of blinded ACE inhibition with trandolapril (2 mg/day) or to non-ACE inhibitor therapy. Treatment was titrated to systolic/diastolic blood pressure <130/80 mmHg. ECG readings were centralized and blinded to treatment. RESULTS—Baseline characteristics of the two groups were similar. Over a median (interquartile range) follow-up of 36 (24–48) months, 13 of the 423 patients (3.1%) receiving trandolapril compared with 31 of the 376 patients (8.2%) receiving non-ACE inhibitor therapy developed ECG-LVH (hazard ratio [HR] 0.34 [95% CI 0.18–0.65], P = 0.0012 unadjusted, and 0.35 [0.18–0.68], P = 0.0018 adjusted for predefined baseline covariates). The HR was significant even after adjustment for follow-up blood pressure and blood pressure reduction versus baseline. Compared with baseline, both Sokolow-Lyon and Cornell voltages significantly decreased with trandolapril but did not change with non-ACE inhibitor therapy. CONCLUSIONS—ACE inhibition has a specific protective effect against the development of ECG-LVH that is additional to its blood pressure–lowering effect. Because ECG-LVH is a strong cardiovascular risk factor in people with hypertension and diabetes, early ACE inhibition may be cardioprotective in this population. American Diabetes Association 2008-08 /pmc/articles/PMC2494629/ /pubmed/18443191 http://dx.doi.org/10.2337/dc08-0371 Text en Copyright © 2008, American Diabetes Association Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See http://creativecommons.org/licenses/by-nc-nd/3.0/ for details. |
spellingShingle | Cardiovascular and Metabolic Risk Ruggenenti, Piero Iliev, Ilian Costa, Grazia Maria Parvanova, Aneliya Perna, Annalisa Giuliano, Giovanni Antonio Motterlini, Nicola Ene-Iordache, Bogdan Remuzzi, Giuseppe Preventing Left Ventricular Hypertrophy by ACE Inhibition in Hypertensive Patients With Type 2 Diabetes: A prespecified analysis of the Bergamo Nephrologic Diabetes Complications Trial (BENEDICT) |
title | Preventing Left Ventricular Hypertrophy by ACE Inhibition in Hypertensive Patients With Type 2 Diabetes: A prespecified analysis of the Bergamo Nephrologic Diabetes Complications Trial (BENEDICT) |
title_full | Preventing Left Ventricular Hypertrophy by ACE Inhibition in Hypertensive Patients With Type 2 Diabetes: A prespecified analysis of the Bergamo Nephrologic Diabetes Complications Trial (BENEDICT) |
title_fullStr | Preventing Left Ventricular Hypertrophy by ACE Inhibition in Hypertensive Patients With Type 2 Diabetes: A prespecified analysis of the Bergamo Nephrologic Diabetes Complications Trial (BENEDICT) |
title_full_unstemmed | Preventing Left Ventricular Hypertrophy by ACE Inhibition in Hypertensive Patients With Type 2 Diabetes: A prespecified analysis of the Bergamo Nephrologic Diabetes Complications Trial (BENEDICT) |
title_short | Preventing Left Ventricular Hypertrophy by ACE Inhibition in Hypertensive Patients With Type 2 Diabetes: A prespecified analysis of the Bergamo Nephrologic Diabetes Complications Trial (BENEDICT) |
title_sort | preventing left ventricular hypertrophy by ace inhibition in hypertensive patients with type 2 diabetes: a prespecified analysis of the bergamo nephrologic diabetes complications trial (benedict) |
topic | Cardiovascular and Metabolic Risk |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2494629/ https://www.ncbi.nlm.nih.gov/pubmed/18443191 http://dx.doi.org/10.2337/dc08-0371 |
work_keys_str_mv | AT ruggenentipiero preventingleftventricularhypertrophybyaceinhibitioninhypertensivepatientswithtype2diabetesaprespecifiedanalysisofthebergamonephrologicdiabetescomplicationstrialbenedict AT ilievilian preventingleftventricularhypertrophybyaceinhibitioninhypertensivepatientswithtype2diabetesaprespecifiedanalysisofthebergamonephrologicdiabetescomplicationstrialbenedict AT costagraziamaria preventingleftventricularhypertrophybyaceinhibitioninhypertensivepatientswithtype2diabetesaprespecifiedanalysisofthebergamonephrologicdiabetescomplicationstrialbenedict AT parvanovaaneliya preventingleftventricularhypertrophybyaceinhibitioninhypertensivepatientswithtype2diabetesaprespecifiedanalysisofthebergamonephrologicdiabetescomplicationstrialbenedict AT pernaannalisa preventingleftventricularhypertrophybyaceinhibitioninhypertensivepatientswithtype2diabetesaprespecifiedanalysisofthebergamonephrologicdiabetescomplicationstrialbenedict AT giulianogiovanniantonio preventingleftventricularhypertrophybyaceinhibitioninhypertensivepatientswithtype2diabetesaprespecifiedanalysisofthebergamonephrologicdiabetescomplicationstrialbenedict AT motterlininicola preventingleftventricularhypertrophybyaceinhibitioninhypertensivepatientswithtype2diabetesaprespecifiedanalysisofthebergamonephrologicdiabetescomplicationstrialbenedict AT eneiordachebogdan preventingleftventricularhypertrophybyaceinhibitioninhypertensivepatientswithtype2diabetesaprespecifiedanalysisofthebergamonephrologicdiabetescomplicationstrialbenedict AT remuzzigiuseppe preventingleftventricularhypertrophybyaceinhibitioninhypertensivepatientswithtype2diabetesaprespecifiedanalysisofthebergamonephrologicdiabetescomplicationstrialbenedict AT preventingleftventricularhypertrophybyaceinhibitioninhypertensivepatientswithtype2diabetesaprespecifiedanalysisofthebergamonephrologicdiabetescomplicationstrialbenedict |